Table 3.
PR of screening non-participation by the selected CDGs ≤2 years and >2–10 years before screening (n = 144,264)
| Unadjusted | Model 1a | Model 2b | ||||
|---|---|---|---|---|---|---|
| ≤2 years | >2–10 years | ≤2 years | >2–10 years | ≤2 years | >2–10 years | |
| PR (95 % CI) | PR (95 % CI) | PR (95 % CI) | PR (95 % CI) | PR (95 % CI) | PR (95 % CI) | |
| Cardiovascular diseases | ||||||
| No | 1 (ref) | 1 (ref) | 1 (ref) | 1 (ref) | 1 (ref) | 1 (ref) |
| Yes | 1.24 (1.16–1.31) | 1.16 (1.11–1.21) | 1.13 (1.06–1.21) | 1.04 (0.99–1.09) | 1.05 (0.99–1.13) | 0.98 (0.93–1.02) |
| Cancer | ||||||
| No | 1 (ref) | 1 (ref) | 1 (ref) | 1 (ref) | 1 (ref) | 1 (ref) |
| Yes | 1.63 (1.54–1.74) | 1.19 (1.11–1.27) | 1.56 (1.46–1.66) | 1.16 (1.08–1.24) | 1.50 (1.40–1.60) | 1.10 (1.03–1.17) |
| Hypertension | ||||||
| No | 1 (ref) | 1 (ref) | 1 (ref) | 1 (ref) | 1 (ref) | 1 (ref) |
| Yes | 1.00 (0.91–1.09) | 0.99 (0.93–1.06) | 0.97 (0.87–1.07) | 0.97 (0.91–1.04) | 0.92 (0.83–1.02) | 0.93 (0.87–0.99) |
| Chronic mental illness | ||||||
| No | 1 (ref) | 1 (ref) | 1 (ref) | 1 (ref) | 1 (ref) | 1 (ref) |
| Yes | 1.93 (1.82–2.04) | 1.78 (1.71–1.86) | 1.62 (1.53–1.71) | 1.51 (1.44–1.57) | 1.51 (1.42–1.60) | 1.40 (1.35–1.46) |
| Diabetes | ||||||
| No | 1 (ref) | 1 (ref) | 1 (ref) | 1 (ref) | 1 (ref) | 1 (ref) |
| Yes | 1.27 (1.19–1.36) | 1.41 (1.33–1.50) | 1.14 (1.06–1.22) | 1.23 (1.17–1.31) | 1.05 (0.97–1.13) | 1.10 (1.04–1.17) |
| Chronic obstructive pulmonary disease | ||||||
| No | 1 (ref) | 1 (ref) | 1 (ref) | 1 (ref) | 1 (ref) | 1 (ref) |
| Yes | 1.87 (1.75–1.99) | 1.68 (1.59–1.78) | 1.62 (1.52–1.73) | 1.43 (1.35–1.52) | 1.51 (1.42–1.62) | 1.32 (1.24–1.40) |
| Chronic neurological disorders | ||||||
| No | 1 (ref) | 1 (ref) | 1 (ref) | 1 (ref) | 1 (ref) | 1 (ref) |
| Yes | 1.50 (1.35–1.65) | 1.57 (1.44–1.71) | 1.36 (1.23–1.50) | 1.40 (1.29–1.52) | 1.24 (1.12–1.37) | 1.23 (1.13–1.34) |
| Chronic arthritis | ||||||
| No | 1 (ref) | 1 (ref) | 1 (ref) | 1 (ref) | 1 (ref) | 1 (ref) |
| Yes | 1.02 (0.90–1.15) | 1.04 (0.94–1.16) | 0.97 (0.86–1.10) | 0.99 (0.89–1.11) | 0.90 (0.80–1.02) | 0.89 (0.80–1.00) |
| Chronic bowel disease | ||||||
| No | 1 (ref) | 1 (ref) | 1 (ref) | 1 (ref) | 1 (ref) | 1 (ref) |
| Yes | 0.80 (0.68–0.94) | 0.79 (0.69–0.90) | 0.81 (0.69–0.94) | 0.78 (0.68–0.89) | 0.75 (0.65–0.88) | 0.71 (0.61–0.81) |
| Chronic liver disease | ||||||
| No | 1 (ref) | 1 (ref) | 1 (ref) | 1 (ref) | 1 (ref) | 1 (ref) |
| Yes | 1.40 (1.17–1.67) | 1.47 (1.26–1.72) | 1.20 (1.00–1.43) | 1.24 (1.06–1.43) | 1.12 (0.93–1.34) | 1.08 (0.92–1.26) |
| Chronic kidney disease | ||||||
| No | 1 (ref) | (ref) | 1 (ref) | 1 (ref) | 1 (ref) | 1 (ref) |
| Yes | 2.22 (1.94–2.55) | 1.83 (1.57–2.14) | 1.93 (1.69–2.20) | 1.61 (1.36–1.90) | 1.70 (1.49–1.94) | 1.40 (1.19–1.65) |
aAdjusted for age, ethnicity, marital status and education
bAdjusted for age, ethnicity, marital status, education, for being registered in the NPR or PCRR with the other studied chronic diseases, and for being registered in the NPR or PCRR with one of the CDGs in the other time period (yes/no). E.g. cancer 0–2 year before screening is adjusted for SEP, for the remaining 10 studied diseases and for being in hospital contact with one of the 11 included chronic disease groups >2–10 years before screening
Statistically significant results in bold